Portal de Periódicos da CAPES

A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression

2024; Nature Portfolio; Volume: 9; Issue: 1 Linguagem: Inglês

10.1038/s41541-024-00813-3

2059-0105

Huajun Zhao, Xianyu Shao, Yating Yu, Lulu Huang, Narh Philip Amor, Kundian Guo, Changzhen Weng, Weijun Zhao, Ailu Yang, Jiesen Hu, Hongbao Yang, Zhenguang Liu, Qiuju Han, Leilei Shi, Shiyu Sun, Jian Zhang, Ang Lin, Yong Yang,

RNA Interference and Gene Delivery

Abstract Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.